ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

BRCA 1 Mutation Finding Draws Attention To Potential Perils Of Genetic Testing

October 6, 1995

Antman, Clanton begin work at NCI.

December 5, 2003

TGen At Scottsdale Opens Clinical Trial Of OSI-906 For Adrenocortical Carcinoma

September 25, 2009

Job Discrimination Survey Completed, But NCI Still Trying To Interpret I; Payments May Be Held Up

August 19, 1977

White House Yet To Name NCAB, Cancer Panel Members

February 11, 2011